Recombinant tissue plasminogen activator treatment for COVID-19 associated ARDS and acute cor pulmonale.

Abstract

Existing literature highlights the fact that patients with COVID-19 exhibit alterations in the coagulation process and are associated with respiratory and cardiovascular diseases, including acute respiratory distress syndrome and acute cor pulmonale. In this report, we describe the effects of systemic thrombolysis on acute cor pulmonale in a patient suffering from COVID-19. We demonstrated that systemic thrombolysis successfully improved the hemodynamics of our patient and resulted in a prominent reduction in hypercapnia, alveolar dead space, and ventilatory ratio.

• Authors: Djuro Kosanovic, Andrey I Yaroshetskiy, Natalia A Tsareva, Zamira M Merzhoeva, Natalia V Trushenko, Galina V Nekludova, Ralph Theo Schermuly, Sergey N Avdeev
• Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (Int J Infect Dis) Vol. 104 Pg. 108-110 (Mar 2021) ISSN: 1878-3511 [Electronic] Canada
• PMID: 33352323 (Publication Type: Case Reports)
• Copyright: Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Chemical References

• Recombinant Proteins
• Tissue Plasminogen Activator

Topics

• Acute Disease
• Aged
• COVID-19 (complications, virology)
• Heart Failure (diagnostic imaging, drug therapy, etiology)
• Humans
• Male
• Recombinant Proteins
• Respiratory Distress Syndrome (diagnostic imaging, drug therapy, etiology)
• SARS-CoV-2 (physiology)
• Thrombolytic Therapy
• Tissue Plasminogen Activator (therapeutic use)